Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Global biopharma and life sciences companies provide updates to their businesses and pipelines.
Here’s the shortlist of which life sciences companies took a dip in the money pool this week.
The companies will use their funds to support the development of their lead assets and advance their pipelines.
The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
Two months after Athira placed its CEO Leen Kawas, on temporary leave, the company has appointed new execs to its team. It is also rigorously advancing its Alzheimer’s program.
CureVac has revealed in its latest financial report that its lung cancer program with German biotechnology company Boehringer Ingelheim has been terminated.
Eli Lilly is undertaking a strategic transformation that will result in the formation of new business units.
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
Vivek Ramaswamy is launching a book that represents the social injustice in society. Read the article to get some information about the book and its author.
Codiak has two engineered exosome programs in Phase I, each showing different types of engineering possibilities to deliver targeted payloads that pharmaceutical companies haven’t managed to push all the way through the clinic.